Vertex soars on new CF data

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) jumped $32.73 (62%) to $86.60 on Friday after reporting data late Thursday from a Phase II trial of VX-661 to treat cystic fibrosis (CF). The move translates ...